Advantage of using a recombinant activated factor VII in traumatic haemorrhagic shock: The Bordeaux experience
Journal of Emergencies, Trauma and Shock, 05/25/2012
Morel N et al. – The findings suggest that it seems legitimate to recommend earlier use of rFVIIa in cases of traumatic haemorrhagic shock in the context of haematological damage control combined with the use of an algorithm to predict the risk involved in polytransfusion and a more aggressive transfusion strategy.
Twenty-seven patients treated with rFVIIa after a traumatic injury between May 2005 and December 2008 were included.
Average age was 46years old.
Eighty per cent of patients were polytransfused.
Mortality rate was 33%.
Adjusted mortality rate, using the Boffard study criteria, was 8.3%.
The authors observed significant differences between the group of patients who died and the group of survivors in pH, PT, Hb, ionised calcaemia, temperature and platelet count.
They observed significant differences between the successful rFVIIa group and the failed rFVIIa group in pH, Hb, platelet count and ionised calcaemia.
Ten patients had an rFVIIa injection only and 17 patients had an rFVIIa injection combined with a mechanical procedure to stop the bleeding.
Two patients presented with thromboembolic complications.
They observed a tendency to recommend an rFVIIa injection before radical treatment is applied.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.